Goldman Sachs Group Inc reissued their conviction-buy rating on shares of Shire PLC (LON:SHP) in a research report sent to investors on Thursday. The brokerage currently has a GBX 6,800 ($83.98) price target on the biopharmaceutical company’s stock.
Other analysts have also issued reports about the stock. Deutsche Bank AG restated a buy rating and issued a GBX 6,300 ($77.81) price objective on shares of Shire PLC in a report on Friday, February 17th. JPMorgan Chase & Co. restated an overweight rating and issued a GBX 6,300 ($77.81) price objective on shares of Shire PLC in a report on Monday, December 5th. Liberum Capital restated a buy rating and issued a GBX 5,500 ($67.93) price objective on shares of Shire PLC in a report on Tuesday, January 31st. Jefferies Group LLC restated a buy rating and issued a GBX 6,600 ($81.51) price objective on shares of Shire PLC in a report on Thursday, January 5th. Finally, Societe Generale lowered their price objective on shares of Shire PLC from GBX 6,500 ($80.28) to GBX 6,200 ($76.57) and set a buy rating for the company in a report on Monday, March 6th. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of GBX 6,115.60 ($75.53).
Shire PLC (LON:SHP) opened at 4759.00 on Thursday. The company’s market capitalization is GBX 42.96 billion. The stock has a 50 day moving average price of GBX 4,742.35 and a 200 day moving average price of GBX 4,766.87. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00.
Your IP Address:
The firm also recently announced a dividend, which will be paid on Tuesday, April 25th. Stockholders of record on Thursday, March 9th will be issued a dividend of GBX 20.64 ($0.25) per share. This represents a dividend yield of 0.43%. This is a positive change from Shire PLC’s previous dividend of $3.51. The ex-dividend date of this dividend is Thursday, March 9th.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.